Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MicroRNAs (miRNAs) regulate a variety of development and physiologic processes, and play prominent roles in the initiation and progression of human cancers including
hepatocellular carcinoma
(
HCC
). MiR-23c is recently emerging as a cancer-associated miRNA, while its expression status and functional role in
HCC
are unrevealed yet. Here, we found that miR-23c underexpression was associated with the tumorigenesis of
HCC
based on TCGA data. qRT-PCR analysis revealed that miR-23c expression was reduced in
HCC
tissues and cell lines. Clinical analysis indicated that low miR-23c expression was correlated with large tumor size, high tumor grade, advanced tumor stage and poor survival of
HCC
patients. Our in vitro experiments found that overexpression of miR-23c inhibited cell proliferation and induced apoptosis of
HCC
cells. While miR-23c knockdown led to
HCC
cell growth arrest and apoptosis. Additionally, miR-23c overexpression repressed tumor growth of
HCC
in vivo. Mechanistically,
erbb2 interacting protein
(
ERBB2IP
) was identified as a direct target of miR-23c in
HCC
cells. miR-23c suppressed
ERBB2IP
expression in
HCC
cells and inversely correlated with
ERBB2IP
mRNA expression in
HCC
tissues. Notably,
ERBB2IP
silencing restrained
HCC
cell proliferation and induced apoptosis.
ERBB2IP
restoration reversed the inhibitory effects of miR-23c on
HCC
cell growth. In conclusion, our observations suggested that miR-23c inhibited cell proliferation and accelerated apoptosis by attenuating
ERBB2IP
. Targeting miR-23c might open a new avenue for
HCC
treatment.
...
PMID:miR-23c suppresses tumor growth of human hepatocellular carcinoma by attenuating ERBB2IP. 3010 14
Long non-coding RNAs (lncRNAs) are critical regulators in the tumorigenesis and metastasis of
hepatocellular carcinoma
(
HCC
). LncRNA KTN1 antisense RNA 1 (KTN1-AS1) has been reported to play an important role in colorectal cancer and correlates with unfavorable clinical outcomes of head and neck squamous cell carcinoma. However, the clinical significance and functional role of KTN1-AS1 in
HCC
are still unclear. Here, we found that KTN1-AS1 was a highly expressed lncRNA in
HCC
according to public available databases and our
HCC
cohort. Further analyses revealed that higher expression of KTN1-AS1 was observed in
HCC
tissues with large tumor size, high tumor grade and advanced TNM stage. Analysis of survival data indicated that high KTN1-AS1 expression was prominently correlated with poor clinical outcomes of
HCC
patients. Functionally, KTN1-AS1 knockdown suppressed cell proliferation and colony formation, and increased apoptosis of SMMC-7721 cells in vitro. Furthermore, silencing of KTN1-AS1 restrained tumor growth of
HCC
in vivo. Conversely, forced expression of KTN1-AS1 facilitated Huh7 cell proliferation and inhibited apoptosis. Mechanistically, KTN1-AS1 inversely regulated miR-23c abundance in
HCC
cells. Further evidence supported that KTN1-AS1 acted as a competing endogenous RNA (ceRNA) by directly sponging miR-23c in
HCC
cells. Interestingly,
erbb2 interacting protein
(
ERBB2IP
), a known target of miR-23c, was positively regulated by KTN1-AS1 and its restoration reversed KTN1-AS1 knockdown attenuated
HCC
cell growth. To conclude, our study sheds light on the novel function and underlying mechanism of KTN1-AS1 in
HCC
, which may accelerate the development of cancer therapy.
...
PMID:LncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. 3055 64